Last Thursday brought the shock announcement that Novo Nordisk had made a fresh play to buy the biotech, despite Pfizer ...

A long-running confirmatory trial of two of Sarepta Therapeutics’ Duchenne muscular dystrophy drugs has missed its main goal.

Neok Bio has exited stealth with $75 million to take a pair of bispecific antibody-drug conjugates sourced from ABL Bio into ...

Korean biosimilar specialist Celltrion has penned a deal worth more than $740 million biobucks for two preclinical autoimmune ...

Merck & Co. began Tuesday with back-to-back deals, revealing separate agreements to pay $150 million upfront for full control of an early-phase asset and pocket $700 million to support an expansive ...

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

The precision oncology biotech is pausing work on SMARCA2 degraders and selling a licensing option to Incyte Therapeutics.

Boehringer Ingelheim’s busy year of dealmaking is showing no signs of slowing, with the German pharma now turning to established partner CDR-Life for a new trispecific autoimmune antibody. | ...

Olympus has issued updated corrective action related to the 2023 recall of more than 17,600 bronchoscopes that included flexible, fiber-optic systems and video-camera-equipped devices used to observe ...

After discussions with the FDA, Nuvation disclosed that it has “decided not to pursue a head-to-head randomized study of safusidenib against vorasidenib to support approval in non-enhancing grade 2 ...

The FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the ...

TScan Therapeutics is laying off 30% of its workforce as the T-cell receptor (TCR) therapy biotech abandons a phase 1 solid ...